vimarsana.com

Page 3 - Tulane Cancer Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Making Magic Happen in Cancer Care

During an uncertain time, Missy Bean-Tanner, RN, brings inner peace and reassurance. She will jump into anything if she knows it will help her patients.

2023 - Alumni in the spotlight April 2023 - Wits University

2023 - Alumni in the spotlight April 2023 - Wits University
wits.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wits.ac.za Daily Mail and Mail on Sunday newspapers.

Treatment Vs No Treatment of Localized Prostate Cancer Had Similar Results Over 15 Years, 1 Question Raised

Dr Stefan C Grant to serve as Section Chief of Hematology and Medical Oncology

FDA Approves Expanded Indication for Telix s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy

MELBOURNE, Australia, March 16, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom lutetium-177 (177Lu) PSMA-directed therapy is indicated.[1] The label expansion means Illuccix is now approved in the U.S. to identify and select patients who are candidates for the only FDA-approved prostate-specific membrane antigen (PSMA)- directed radioligand therapy (Pluvicto),[2] providing doctors with critical information to guide patient management and help optimise treatment outcomes. To qualify for radioligand therapy, patients must be imaged with an approved gallium-based PSMA-PET agent.[3] As the only diagnostic agent for prostate cancer that combines the accuracy of gall

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.